Huaiqi Yao1, Xuanzhi Liu1, Suzuan Chen2, Wei Xia3, Xiaojun Chen2. 1. Department of Ultrasound, The First Affiliated Hospital of Shantou University Medical College Shantou 515041, Guangdong Province, China. 2. Department of Gastroenterology, The First Affiliated Hospital of Shantou University Medical College Shantou 515041, Guangdong Province, China. 3. Department of Intervention, The First Affiliated Hospital of Shantou University Medical College Shantou 515041, Guangdong Province, China.
Abstract
BACKGROUND: MicroRNAs (miRNAs) play important roles in many important cellular processes and deregulation of miRNAs is linked to many human diseases including cancer. Although miR-424 has been demonstrated to inhibit progression of hepatocellular carcinoma (HCC), its expression level in serum samples and the potential clinical values remain unknown. MATERIALS AND METHODS: The expression level of miR-424 in the serum clinical samples from HCC patients and healthy volunteers were determined by qRT-PCR. Then the association of serum miR-424 expression level with various important clinicopathological parameters and survival rates was evaluated. Multivariate Cox regression analysis was used to identify the independent risk factors for HCC. RESULTS: The expression level of serum miR-424 was significantly decreased in patients with HCC compared with the healthy volunteers (P<0.01). Reduced expression of serum miR-424 was associated with serum AFP (P=0.048), vein invasion (P=0.006) and TNM stage (P=0.003). In addition, survival analysis showed that HCC patients with lower serum miR-424 expression suffered poorer overall survival (P=0.018) and disease free survival (P=0.008). Moreover, serum miR-424 was demonstrated to be an independent risk factor for HCC. CONCLUSIONS: Our findings provide the compelling evidence that the decreased expression of serum miR-424 may serve as a novel biomarker to predict the unfavorable prognosis of HCC patients.
BACKGROUND: MicroRNAs (miRNAs) play important roles in many important cellular processes and deregulation of miRNAs is linked to many human diseases including cancer. Although miR-424 has been demonstrated to inhibit progression of hepatocellular carcinoma (HCC), its expression level in serum samples and the potential clinical values remain unknown. MATERIALS AND METHODS: The expression level of miR-424 in the serum clinical samples from HCC patients and healthy volunteers were determined by qRT-PCR. Then the association of serum miR-424 expression level with various important clinicopathological parameters and survival rates was evaluated. Multivariate Cox regression analysis was used to identify the independent risk factors for HCC. RESULTS: The expression level of serum miR-424 was significantly decreased in patients with HCC compared with the healthy volunteers (P<0.01). Reduced expression of serum miR-424 was associated with serum AFP (P=0.048), vein invasion (P=0.006) and TNM stage (P=0.003). In addition, survival analysis showed that HCC patients with lower serum miR-424 expression suffered poorer overall survival (P=0.018) and disease free survival (P=0.008). Moreover, serum miR-424 was demonstrated to be an independent risk factor for HCC. CONCLUSIONS: Our findings provide the compelling evidence that the decreased expression of serum miR-424 may serve as a novel biomarker to predict the unfavorable prognosis of HCC patients.
Authors: Jill Samis; Elio F Vanin; Simone Treiger Sredni; Maria de Fátima de Bonaldo; Fabricio F Costa; Tadanori Tomita; Reema Habiby; Donald Zimmerman; Marcelo B Soares Journal: Childs Nerv Syst Date: 2016-06-07 Impact factor: 1.475
Authors: André R C P de Oliveira; Márcia M U Castanhole-Nunes; Patrícia M Biselli-Chicote; Érika C Pavarino; Rita de C M A da Silva; Renato F da Silva; Eny M Goloni-Bertollo Journal: Arch Med Sci Date: 2020-08-10 Impact factor: 3.318
Authors: Dengdi Hu; Dan Shen; Min Zhang; Nengmeng Jiang; Feng Sun; Shibo Yuan; Kaiming Wan Journal: Am J Cancer Res Date: 2017-10-01 Impact factor: 6.166
Authors: Antonino Belfiore; Roberta Malaguarnera; Veronica Vella; Michael C Lawrence; Laura Sciacca; Francesco Frasca; Andrea Morrione; Riccardo Vigneri Journal: Endocr Rev Date: 2017-10-01 Impact factor: 19.871